US Stock MarketDetailed Quotes

SAVA Cassava Sciences

Watchlist
  • 1.700
  • -0.050-2.86%
Close Mar 27 16:00 ET
  • 1.700
  • 0.000-0.01%
Post 20:01 ET
82.12MMarket Cap-1.16P/E (TTM)

About Cassava Sciences Company

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Company Profile

SymbolSAVA
Company NameCassava Sciences
Listing DateJul 14, 2000
Issue Price12.00
Founded1998
CEOMr. Richard J. Barry
MarketNASDAQ
Employees30
Fiscal Year Ends12-31
Address6801 North Capital of Texas Highway,Suite 300
CityAustin
ProvinceTexas
CountryUnited States of America
Zip Code78731
Phone1-512-501-2444

Company Executives

  • Name
  • Position
  • Salary
  • Richard J. Barry
  • President, Chief Executive Officer and Director
  • 546.16K
  • Eric Schoen
  • Chief Financial Officer and Principal Accounting Officer
  • 2.99M
  • Dr. James W. Kupiec, M.D.
  • Chief Medical Officer and Chief Clinical Development Officer
  • 2.97M
  • R. Christopher Cook
  • Senior Vice President and General Counsel
  • 1.27M
  • Dr. Claude Nicaise,M.D.
  • Chairman of the Board
  • 474.50K
  • Sanford R. Robertson
  • Lead Independent Director
  • 546.16K
  • Robert Anderson, Jr
  • Independent Director
  • 474.50K
  • Pierre Gravier
  • Independent Director
  • 474.50K
  • Michael J. O'Donnell, Esq.
  • Independent Director
  • 438.42K
  • Dr. Robert Z. Gussin, PhD
  • Independent Director
  • 546.16K
  • Dr. Patrick J. Scannon,M.D.,PhD
  • Independent Director
  • 438.42K

Market Insights

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More